Evidence map›Paper›PMID 31255591›Full record

Trial reportThe Lancet. Global health2019

Evaluation of integrated interventions layered on mass drug administration for urogenital schistosomiasis elimination: a cluster-randomised trial.

Stefanie Knopp, Bobbie Person, Shaali M Ame, Said M Ali, Jan Hattendorf, Saleh Juma, Juma Muhsin, Iddi S Khamis, Khalfan A Mohammed, Jürg Utzinger and 3 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The Lancet. Global health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 5 pooled it
10.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 5 syntheses or guidelines pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Effectiveness of Four Different Interventions Against Schistosoma haematobium in a Seasonal Transmission Setting of Côte d'Ivoire: A Cluster Randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. SCORE Operational Research on Moving toward Interruption of Schistosomiasis Transmission.The American journal of tropical medicine and hygiene · 2020
    Trial
  13. Trial
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 4 countries.

Stefanie KnoppSwiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland; Wolfson Wellcome Biomedical Laboratories, Department of Life Sciences, Natural History Museum, London, UK. Electronic address: s.knopp@swisstph.ch.
Bobbie PersonSchistosomiasis Consortium for Operational Research and Evaluation, University of Georgia, Athens, GA, USA.
Shaali M AmePublic Health Laboratory-Ivo de Carneri, Pemba, Tanzania.
Said M AliPublic Health Laboratory-Ivo de Carneri, Pemba, Tanzania.
Jan HattendorfSwiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.
Saleh JumaPublic Health Laboratory-Ivo de Carneri, Pemba, Tanzania.
Juma MuhsinNeglected Diseases Programme, Ministry of Health, Zanzibar, Tanzania.
Iddi S KhamisNeglected Diseases Programme, Ministry of Health, Zanzibar, Tanzania.
Khalfan A MohammedNeglected Diseases Programme, Ministry of Health, Zanzibar, Tanzania.
Jürg UtzingerSwiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.
Elizabeth HollenbergSchistosomiasis Control Initiative, Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College London, London, UK.
Fatma KaboleNeglected Diseases Programme, Ministry of Health, Zanzibar, Tanzania.
David RollinsonWolfson Wellcome Biomedical Laboratories, Department of Life Sciences, Natural History Museum, London, UK.
Zanzibar University · TZPublic Health Laboratory Ivo de Carneri · TZNatural History Museum · GBSwiss Tropical and Public Health Institute · CHImperial College London · GBUniversity of Georgia · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundElimination of schistosomiasis as a public health problem and interruption of transmission in selected areas are targets set by WHO for 2025. Our aim was to assess biannual mass drug administration (MDA) applied alone or with complementary snail control or behaviour change interventions for the reduction of Schistosoma haematobium prevalence and infection intensity in children from Zanzibar and to compare the effect between the clusters.

methodsIn a 5-year repeated cross-sectional cluster-randomised trial, 90 shehias (small administrative regions; clusters) in Zanzibar eligible owing to available natural open freshwater bodies and public primary schools were randomly allocated (ratio 1:1:1) to receive one of three interventions: biannual MDA with praziquantel alone (arm 1) or in combination with snail control (arm 2), or behaviour change activities (arm 3). Neither participants nor field or laboratory personnel were blinded to the intervention arms. From 2012 to 2017, annually, a single urine sample was collected from approximately 100 children aged 9-12 years in the main public primary school of each shehia. The primary outcome was S haematobium infection prevalence and intensity in 9-12-year-old children after 5 years of follow-up. This study is completed and was registered with the ISRCTN, number 48837681.

findingsThe trial was done from Nov 1, 2011, through to Dec 31, 2017 and recruitment took place from Nov 2, 2011, until May 17, 2017. At baseline we enrolled 8278 participants, of whom 2899 (35%) were randomly allocated to arm 1, 2741 (33%) to arm 2, and 2638 (32%) to arm 3. 120 (4·2%) of 2853 in arm 1, 209 (7·8%) of 2688 in arm 2, and 167 (6·4%) of 2613 in arm 3 had S haematobium infections at baseline. Heavy infections (≥50 eggs per 10 mL of urine) were found in 126 (1·6%) of 8073 children at baseline. At the 5-year endline survey, 46 (1·4%) of 3184 in arm 1, 56 (1·7%) of 3217 (odds ratio [OR] 1·2 [95% CI 0·6-2·7] vs arm 1) in arm 2, and 58 (1·9%) of 3080 (1·3 [0·6-2·9]) in arm 3 had S haematobium infections. Heavy infections were detected in 33 (0·3%) of 9462 children.

interpretationBiannual MDA substantially reduced the S haematobium prevalence and infection intensity but was insufficient to interrupt transmission. Although snail control or behaviour change activities did not significantly boost the effect of MDA in our study, they might enhance interruption of transmission when tailored to focal endemicity and applied for a longer period. It is now necessary to focus on reducing prevalence in remaining hotspot areas and to introduce new methods of surveillance and public health response so that the important gains can be maintained and advanced.

fundingUniversity of Georgia Research Foundation Inc and Bill & Melinda Gates Foundation.

Indexed as

Delivery of Health Care, IntegratedDisease EradicationAnimalsAnthelminticsChildCluster AnalysisFemaleHealth PromotionHumansMalePraziquantelSchistosoma haematobiumSchistosomiasis haematobiaTanzaniaAnthelminticsPraziquantel

Identifiers

PMID31255591
PMCPMC6624424
OpenAlexW2954791930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.